The Clinical Significance and Mechanisms of REG4 in Human Cancers

Junyan Zhang(China Medical University), Zhenning Wang(First Hospital of China Medical University), Xuanzhang Huang(First Hospital of China Medical University), Huimian Xu(First Hospital of China Medical University), Zhe Sun(Guangzhou University of Chinese Medicine), Zhi‐Feng Miao(Kaohsiung Medical University), Zhi Zhu(Sun Yat-sen University)
Frontiers in Oncology
January 8, 2021
10.3389/fonc.2020.559230
Cited by 24

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion
|Nature Communications|2017|268
Regenerative proliferation of differentiated cells by mTORC1‐dependent paligenosis
|The EMBO Journal|2018|207